e-learning
resources
Stockholm 2007
Sunday 16.09.2007
Pathogenesis and novel therapeutic targets in pulmonary hypertension
Login
Search all ERS
e-learning
resources
Disease Areas
Airways Diseases
Interstitial Lung Diseases
Respiratory Critical Care
Respiratory Infections
Paediatric Respiratory Diseases
Pulmonary Vascular Diseases
Sleep and Breathing Disorders
Thoracic Oncology
Events
International Congress
Courses
Webinars
Conferences
Research Seminars
Journal Clubs
Publications
Breathe
Monograph
ERJ
ERJ Open Research
ERR
European Lung White Book
Handbook Series
Guidelines
All ERS guidelines
e-learning
CME Online
Case reports
Short Videos
SpirXpert
Procedure Videos
CME tests
Reference Database of Respiratory Sounds
Radiology Image Challenge
Brief tobacco interventions
EU Projects
VALUE-Dx
ERN-LUNG
ECRAID
UNITE4TB
Disease Areas
Events
Publications
Guidelines
e-learning
EU Projects
Login
Search
In a model of genetic pulmonary hypertension, VIP attenuates pulmonary vascular remodeling and right ventricular hypertrophy
S. Hamidi, T. Abdel-Razek, A. Szema, S. Said (Stony Brook, NY, Northport, NY, United States Of America)
Source:
Annual Congress 2007 - Pathogenesis and novel therapeutic targets in pulmonary hypertension
Session:
Pathogenesis and novel therapeutic targets in pulmonary hypertension
Session type:
Oral Presentation
Number:
223
Disease area:
Pulmonary vascular diseases
Rating:
You must
login
to grade this presentation.
Share or cite this content
Citations should be made in the following way:
S. Hamidi, T. Abdel-Razek, A. Szema, S. Said (Stony Brook, NY, Northport, NY, United States Of America). In a model of genetic pulmonary hypertension, VIP attenuates pulmonary vascular remodeling and right ventricular hypertrophy. Eur Respir J 2007; 30: Suppl. 51, 223
You must
login
to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
No comment yet.
You must
Login
to comment this presentation.
Related content which might interest you:
Late Breaking Abstract - Implications of treatable traits and treatment choices on exacerbation risk in moderate-severe asthma
Observational cohort study of pulmonary exacerbations in alpha-1 antitrypsin deficiency
Impact of Dexamethasone on pathogen profile of COVID-19 patients requiring intensive care: a multicentre retrospective study
Related content which might interest you:
Vascular and right ventricular remodelling in chronic thromboembolic pulmonary hypertension
Source: Eur Respir J 2013; 41: 224-232
Year: 2013
Involvement of FHL1 in vascular remodelling
Source: Annual Congress 2006 - Lung vascular and parenchymal remodeling
Year: 2006
Serotonin transporter genes, pulmonary haemodynamics and pulmonary hypertension
Source: Annual Congress 2005 - Scientific year in review
Year: 2005
Pulmonary hypertension: the science behind the disease spectrum
Source: Eur Respir Rev 2012; 21: 19-26
Year: 2012
Molecular determinants of cardiac and pulmonary vascular remodeling in scleroderma-related pulmonary hypertension
Source: Annual Congress 2008 - Pulmonary hypertension in connective tissue diseases
Year: 2008
The pathobiology and genetics of pulmonary hypertension
Source: Annual Congress 2006 - Pulmonary hypertension at the crossroads of science and clinical medicine
Year: 2006
Terguride ameliorates monocrotaline-induced pulmonary hypertension in rats
Source: Eur Respir J 2011; 37: 1104-1118
Year: 2011
Contribution of angiopoietin/Tie2 pathway to pulmonary artery smooth muscle hyperplasia in idiopathic pulmonary hypertension
Source: Annual Congress 2005 - Pulmonary hypertension: pathophysiology
Year: 2005
Partial reversal of experimental pulmonary hypertension by phosphodiesterase-3/4 inhibition
Source: Eur Respir J 2008; 31: 599-610
Year: 2008
PDGF promotes pulmonary artery smooth muscle cell proliferation and migration in pulmonary arterial hypertension
Source: Annual Congress 2006 - Signalisation in the pulmonary vasculature: new pathways and wrong signals
Year: 2006
Effects of erythropoietin on advanced pulmonary vascular remodelling
Source: Eur Respir J 2008; 31: 126-134
Year: 2008
Chronic thromboembolic pulmonary hypertension: animal models
Source: Eur Respir J 2013; 41: 1200-1206
Year: 2013
Combining bosentan and sildenafil improves mitochondrial capacity and restores right ventricular contractility in established pulmonary hypertension
Source: Annual Congress 2007 - Pathogenesis and novel therapeutic targets in pulmonary hypertension
Year: 2007
The unknown pathophysiological relevance of right ventricular hypertrophy in pulmonary arterial hypertension
Source: Eur Respir J, 53 (4) 1900255; 10.1183/13993003.00255-2019
Year: 2019
2-Ethoxyestradiol inhibits vascular and cardiac remodeling and attenuates monocrotaline-induced pulmonary hypertension
Source: Annual Congress 2007 - Cellular and molecular aspects of pulmonary hypertension
Year: 2007
Carvedilol partially reverses maladaptive remodeling and improves function of the right ventricle (RV) in experimentally-induced pulmonary arterial hypertension (PAH)
Source: Annual Congress 2009 - Pathobiology of pulmonary vascular diseases
Year: 2009
Inhibition of the Rho-kinase attenuates hypoxia-induced angiogenesis in the pulmonary circulation
Source: Annual Congress 2006 - Pulmonary circulation: inflammation and remodelling
Year: 2006
Pulmonary hypertension in chronic obstructive pulmonary disease
Source: Eur Respir J 2003; 21: 892-905
Year: 2003
Mast cells promote lung vascular remodelling in pulmonary hypertension
Source: Eur Respir J 2011; 37: 1400-1410
Year: 2011
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking "Accept", you consent to the use of the cookies.
Accept